Drug Profile
Monoclonal antibody CH14.18-GM-CSF fusion protein
Alternative Names: Ch14.18-GM-CSF; Monoclonal antibody GD2-GM-CSF fusion proteinLatest Information Update: 18 May 2010
Price :
$50
*
At a glance
- Originator Lexigen Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Neuroblastoma
Most Recent Events
- 18 May 2010 Discontinued - Preclinical for Neuroblastoma in USA (unspecified route)
- 02 Feb 2000 New profile
- 02 Feb 2000 Preclinical development for Neuroblastoma in USA (Unknown route)